Convatec sells dressings for slow-healing wounds, pouches for people living with a stoma, catheters for bladder management and the infusion sets that connect insulin pumps to the body. That unglamorous list is the whole point: these are products people need every day, often for years, and reorder with a regularity most consumer brands would envy.
The group makes money by owning strong positions in four chronic-care niches and turning repeat Demand into rising margins. In 2025 it generated Revenue of $2,439m, nearly all from recurring, chronic-condition products. The model is simple: win the patient early, often in hospital, then keep supplying them at home.
The past year has tested that story. A US reimbursement shock all but wiped out one wound-care product, former chief executive Karim Bitar died in service in 2025, and Cash Flow slipped in early 2026. How resilient is the machine underneath?
How the Business makes money
Convatec (LSE:CTEC) reports four categories. In the year to 31 December 2025, Advanced Wound Care (excluding the InnovaMatrix skin substitute) brought in $684m, Ostomy Care $676m, Continence Care $537m and Infusion Care $473m.
Wound care centres on dressings such as its AQUACEL range, sold mainly to hospitals and community care providers. Ostomy Care supplies pouches and accessories to people who have had bowel or bladder surgery; the newer Esteem Body range had reached annualised revenue of roughly $60m by mid-2026, with management estimating about a 15% share of its segment. Continence Care is heavily US-weighted, supplying intermittent catheters directly to patients' homes. Infusion Care makes disposable sets used with insulin pumps and other devices, largely supplied to pump manufacturers.
The common thread is consumables. Once a patient is established on a product, switching is uncommon, giving the group good revenue visibility.
Recent performance
Full-year 2025 was solid. Revenue rose 6.5% on a reported basis, with organic growth of 6.4% excluding InnovaMatrix and 4.8% including it. Infusion Care led the way with organic growth of 12.5%. Adjusted operating profit reached $544m, a Margin of 22.3%, up 110 basis points. Adjusted diluted EPS climbed 16% to 17.6 cents, while reported diluted EPS was 8.6 cents. The full-year Dividend rose 13% to 7.244 cents and a $300m buyback was completed. Net Debt ended the year at $1,330m, around 2.0 times adjusted EBITDA.
The six months to 30 June 2026 were more mixed. Revenue grew 4.4% to $1,232m, but organic growth excluding InnovaMatrix slowed to 5.0% from 6.8% a year earlier, and fell to 1.8% once InnovaMatrix was included. By category, Infusion Care grew 7.4%, Continence Care 5.9%, Ostomy Care 4.3% and Advanced Wound Care (ex-InnovaMatrix) 3.4%.
Adjusted operating profit rose 3.9% to $262m, giving a margin of 21.2%, broadly flat, though up 50 basis points at constant currency. Adjusted diluted EPS rose 6.3% to 8.5 cents. Reported numbers were weaker: operating profit fell to $115m from $179m after a $69m non-cash Impairment on InnovaMatrix, and reported diluted EPS dropped to 2.7 cents.
Cash disappointed. Free cash flow to Equity fell to $22m from $98m, hit by a $146m working-capital outflow and higher tax payments. Net debt rose to $1,534m, or 2.3 times adjusted EBITDA. Management says the inventory and payables effects should reverse in the second half. The Interim Dividend was nonetheless lifted 15.4% to 2.166 cents, and a further $200m buyback, due to complete by 31 December 2026, was announced.
Strategy and catalysts
The InnovaMatrix saga explains much of the recent noise. On 31 October 2025, US Medicare set a new payment rate of $127.28 per square centimetre for skin substitutes, which Convatec describes as an 85% price cut for the product. InnovaMatrix revenue had already dropped 30% to $69m in 2025; in the first half of 2026 it collapsed 94% to $2.5m. The group now expects $5m–$10m for the full year, a headwind of about 2.5% to group revenue. The drag should largely wash out from 2027.
In April 2026 Convatec held a Capital markets day and unveiled its "Accelerate" strategy, the successor to its earlier FISBE plan. It targets organic revenue growth of 6–8% a year from 2027, an adjusted Operating Margin of 24–26%, double-digit annual EPS growth and double-digit growth in free cash flow to equity. The plan leans on innovation: eight new chronic-care products are due across 2026 and 2027, including the ConvaNiox nitric oxide platform and the ConvaVAC negative-pressure dressing.
In August, 2026 guidance was confirmed, with organic growth excluding InnovaMatrix narrowed to 5.5–6.5%, implying second-half growth of 6–8%, plus an adjusted margin of at least 23% and double-digit adjusted EPS growth. Delivering that step-up is the next test.
Valuation talking points
The case rests on compounding Earnings rather than a single catalyst. Adjusted EPS has grown at a double-digit pace, $500m of Buybacks across 2025 and 2026 are shrinking the share count, and the dividend is growing faster than profits. If margins move from 22.3% towards the mid-20s, earnings could outpace sales for years.
Against that, the gap between adjusted and reported earnings is wide, Leverage has edged up, and investors will want proof that cash generation recovers before crediting the medium-term targets.
The bull case
- The vast majority of revenue comes from repeat-purchase chronic-care consumables, giving unusually predictable demand.
- Infusion Care and Continence Care are growing well, and Esteem Body is running ahead of launch expectations.
- The InnovaMatrix hit is now mostly in the base, which should flatter reported growth from 2027.
- A clear margin roadmap to 24–26% supports double-digit EPS growth, amplified by buybacks.
The bear case
- US policy risk remains live: proposed Medicare competitive bidding for continence supplies could, on management's estimate, cut group sales by 1–2%, though not before 2028.
- First-half organic growth slowed, so the guided second-half acceleration must materialise.
- Free cash flow weakened sharply in H1 2026 and leverage rose to 2.3 times.
- Leadership changed in unhappy circumstances, and the new team must prove it can deliver the Accelerate plan.
The bottom line
Convatec makes money in the least flashy way possible: supplying essential consumables to patients with long-term conditions, again and again. That repeat revenue gives the group its defensive character and its confidence in higher margins.
The InnovaMatrix episode showed how quickly one US reimbursement decision can dent the numbers. Investors will likely focus on two things in the coming months: whether second-half growth accelerates as promised, and whether cash flow rebounds. If both happen, the Accelerate targets will look far more credible.






Please wait processing your request...